DNA Damage Response: Sensing, Signalling, and Repair
DNA damage response (DDR; multi-layered genome surveillance; damage types: oxidative (8-OHdG, 8-oxoG, AP sites, SSBs from ROS), UV (CPD/6-4PP; NER substrates), alkylation (O6-meG; MGMT), DSBs (from ionising radiation, replication fork collapse, topoisomerase II; most cytotoxic)); sensing: RPA-coated ssDNA (ATR) or DSB-Ku70/80 (DNA-PK) or MRN complex (MRE11-RAD50-NBS1; DSB detection → ATM recruitment → ATM autophospho-Ser1981 → active dimers → monomerisation); ATM (serine/threonine kinase; PIKK family; DSB → MRN-ATM → H2AX Ser139 (γH2AX; DSB marker; MDC1 → RNF8/RNF168 → K63-ubiquitin → BRCA1/53BP1 recruitment); CHK2 Thr68 → CDC25A degradation → G1/S arrest; p53 Ser15/20); ATR (ssDNA/RPA → ATRIP → ATR → CHK1 Ser317/345 → CDC25A/B → S/G2 checkpoint); repair pathways: BER (base excision repair; OGG1 removes 8-oxoG; APE1 AP lyase; Polβ; XRCC1/Lig3), NER (nucleotide excision repair; XPC-RAD23B damage recognition; TFIIH helicase; XPA/RPA; Polδ/ε; Lig1), NHEJ (non-homologous end-joining; Ku70/80 DSB binding → DNA-PKcs Ser2056 autophosphorylation → Artemis nuclease → Polμ/λ → Lig4/XRCC4/XLF), HR (homologous recombination; S/G2 only; 5′→3′ resection: MRN-CtIP → RPA-ssDNA → BRCA2-RAD51 filament → strand invasion of sister chromatid → faithful repair).
Spirulina Mechanisms in DNA Damage Response
Nrf2-Driven ROS Reduction: 8-OHdG Prevention
8-OHdG/8-oxoG (8-hydroxy-2′-deoxyguanosine/8-oxoguanine; the most abundant oxidative DNA lesion; formed by •OH (Fenton: Fe2+ + H2O2 → Fe3+ + •OH + OH−) or 1O2 attack on C8 of guanine; mutagenic (G→T transversion if unrepaired before OGG1 BER); urinary 8-OHdG: validated biomarker of systemic oxidative DNA damage; elevated in T2DM, CKD, smoking, ageing)) is prevented by spirulina through Nrf2-antioxidant upregulation: GPx1/GPx4 (+20–40%) → H2O2 → H2O (preventing Fenton •OH generation); Cat (+15–30%) → 2H2O2 → 2H2O + O2; SOD1/2 (+25–40%) → O2•− → H2O2 (substrate for GPx/Cat, not •OH unless free iron present); iron chelation (phycocyanin bilins, polyphenol catechols → Fe2+ chelation → Fenton suppression → •OH prevention); phycocyanobilin (PCB; direct •OH scavenging; rate constant k ≈ 1010 M−1s−1; among fastest known small-molecule •OH scavengers; 0.1–0.5 mM intracellular PCB accumulation in spirulina-supplemented cells → nuclear •OH quenching). Clinical: urinary 8-OHdG −20–40% in spirulina-supplemented T2DM/MetS subjects (12–16 weeks; 6–10g/day).
γH2AX/ATM/p53 Checkpoint Pathway Preservation
γH2AX (H2AX Ser139 phosphorylation by ATM/ATR/DNA-PK at DSBs; visualised as nuclear foci (1 focus ≈ 1 DSB); critical scaffold for DDR factor recruitment: MDC1 → RNF8 → K63-Ub → 53BP1/BRCA1 recruitment; γH2AX dephosphorylation by PP2A/PP4/PP6 marks repair completion; persistent γH2AX = unrepaired DSBs → apoptosis/senescence) reflects DSB load. Spirulina prevents DSB formation (upstream ROS quenching) and supports DSB repair signalling: (1) ATM preservation: phycocyanin reduces oxidative ATM disulfide cross-linking (ATM Cys2991 is oxidation-activated; paradoxically, oxidative ATM activation = low-level ROS sensing pathway; however, excessive ROS → ATM hyperactivation/inactivation depending on redox state; spirulina maintains physiological ATM Cys2991 redox status); (2) p53 Ser15 phosphorylation (ATM/ATR substrate; required for p21(CDKN1A) induction → G1/S arrest, DNA repair time): spirulina does not impair p53 activation; NF-κB-MDM2 axis (NF-κB → MDM2 transcription → p53 K48-ubiquitination → degradation): spirulina NF-κB suppression → MDM2 −15–25% → p53 stabilisation in DNA damage context. Net: γH2AX foci −25–40% in H2O2-challenged spirulina-pretreated cells (prevention predominant; repair speed unaltered).
BER/OGG1 Base Excision Repair Enhancement
OGG1 (8-oxoguanine DNA glycosylase 1; bifunctional BER enzyme; Lys249 active site; excises 8-oxoG opposite Cyt → AP site → AP lyase β-elimination → 3′-phosphate; then APE1 (AP endonuclease 1; APEX1; also a redox co-activator of Nrf2/HIF-1α/NF-κB via Cys65 reduction of TF disulfide bonds) cleaves 5′ to AP site → 1-nt gap → Polβ synthesis → Lig3/XRCC1 ligation; OGG1 activity declines with age (−50% in aged rodent liver vs. young) and is Nrf2-regulated (OGG1 promoter ARE consensus; Nrf2/ARE → OGG1 mRNA +15–25% in spirulina-treated cells)) is supported by spirulina: Nrf2 → OGG1 +15–25% → 8-oxoG clearance rate enhanced; APE1 (APEX1; dual role: redox and BER; Nrf2 target at low doses; spirulina → APE1 +10–20% in HepG2) → AP site incision enhanced; XRCC1 (BER scaffold; Lig3/Polβ interaction) expression supported. Thioredoxin-1 (Trx1; TXNRD1 substrate; Nrf2 target; reduces APE1 Cys65 → active APE1 redox function; maintains Polβ active-site thiols) is upregulated +20–35% → BER efficiency enhanced downstream of Nrf2 activation by spirulina.
Electrophile-DNA Adduct Prevention: NQO1/GST Detoxification
Electrophile-DNA adducts (bulky lesions; benzo[a]pyrene diol epoxide-DNA (BPDE-DNA); acrolein/crotonaldehyde-DNA; 4-NQO-purine adducts; require NER for removal; NER capacity ~75 nt/h in normal cells; overwhelmed by high electrophile load → persistent adducts → G→T/A transversions; bioactivated by CYP1A1/1B1/3A4) are prevented by spirulina through phase II detoxification: Nrf2 → NQO1 (NAD(P)H:quinone oxidoreductase 1; 2-electron reduction → detoxification of quinone electrophiles; also reduces α,β-unsaturated carbonyls; NQO1 +35–55%); Nrf2 → GST (glutathione-S-transferases; GSTA1/GSTM1/GSTP1; conjugate electrophiles with GSH → water-soluble mercapturic acid adducts; export via MRP1/2; GSTM1/T1 null polymorphisms: increased cancer risk; spirulina GSTP1/GSTM1 +15–30%); Nrf2 → AKR (aldo-keto reductases; reduce reactive aldehydes including acrolein → alcohol; +10–20%). Net: comet assay tail DNA (•OH-SSBs + electrophile adduct-induced strand breaks) −25–40% in spirulina-pretreated cells challenged with H2O2 or 4-NQO.
Clinical Outcomes in DNA Damage Response
- Urinary 8-OHdG (oxidative DNA damage biomarker; T2DM/MetS): −20–40%
- γH2AX foci (H2O2 challenge; DSB marker; cell models): −25–40%
- Comet assay tail DNA (SSB/DSB; lymphocytes; 12 weeks): −20–35%
- OGG1 mRNA/activity (Nrf2/ARE; BER capacity): +15–25%
- NQO1 protein (electrophile detoxification; HepG2): +35–55%
- p53 protein (MDM2 reduction; NF-κB suppression; DNA stress models): +10–20%
Dosing and Drug Interactions
Genomic protection/cancer prevention: 5–10g daily long-term; combine with selenium (GPx1 selenoprotein; Se co-provision) and zinc (OGG1/APE1 Zn2+ structural co-factors). Chemotherapy (alkylating agents; cisplatin; cyclophosphamide): Spirulina Nrf2-GST upregulation may theoretically increase platinum detoxification → reduced efficacy; caution warranted; avoid high-dose spirulina during active cytotoxic chemotherapy. Radiotherapy: Spirulina pre-treatment ROS reduction may reduce RT-induced DSBs in normal tissue (radioprotection); however, may reduce tumour RT efficacy if used acutely; timing matters. PARP inhibitors (olaparib): PARP inhibitors exploit HR deficiency (BRCA1/2 mutant); spirulina does not rescue BRCA HR (no direct HR pathway activation); no pharmacological conflict expected. Antioxidant + chemotherapy: High-dose antioxidant supplements + chemotherapy is controversial; spirulina physiological Nrf2 activation is distinct from pharmacological antioxidant loading but same caution applies. Summary: 8-OHdG −20–40%, γH2AX −25–40%, comet −20–35%, NQO1 +35–55%; dosing 5–10g daily. NK concern: moderate (chemotherapy/radiotherapy timing).